###begin article-title 0
###xml 91 96 87 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Uncoupling of the LKB1-AMPKalpha Energy Sensor Pathway by Growth Factors and Oncogenic BRAFV600E
###end article-title 0
###begin p 1
Conceived and designed the experiments: JAR. Performed the experiments: REP FC NC. Analyzed the data: REP JAR. Contributed reagents/materials/analysis tools: GM. Wrote the paper: JAR. Performed the initial proteomic screening: FC NC.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 290 296 290 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 339 342 339 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
Understanding the biochemical mechanisms contributing to melanoma development and progression is critical for therapeutical intervention. LKB1 is a multi-task Ser/Thr kinase that phosphorylates AMPK controlling cell growth and apoptosis under metabolic stress conditions. Additionally, LKB1Ser428 becomes phosphorylated in a RAS-Erk1/2-p90RSK pathway dependent manner. However, the connection between the RAS pathway and LKB1 is mostly unknown.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 296 302 296 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 365 370 365 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 478 483 478 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 671 676 671 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 781 787 781 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 855 860 855 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
###xml 318 323 <span type="species:ncbi:10090">mouse</span>
###xml 414 419 <span type="species:ncbi:10090">mouse</span>
Using the UV induced HGF transgenic mouse melanoma model to investigate the interplay among HGF signaling, RAS pathway and PI3K pathway in melanoma, we identified LKB1 as a protein directly modified by HGF induced signaling. A variety of molecular techniques and tissue culture revealed that LKB1Ser428 (Ser431 in the mouse) is constitutively phosphorylated in BRAFV600E mutant melanoma cell lines and spontaneous mouse tumors with high RAS pathway activity. Interestingly, BRAFV600E mutant melanoma cells showed a very limited response to metabolic stress mediated by the LKB1-AMPK-mTOR pathway. Here we show for the first time that RAS pathway activation including BRAFV600E mutation promotes the uncoupling of AMPK from LKB1 by a mechanism that appears to be independent of LKB1Ser428 phosphorylation. Notably, the inhibition of the RAS pathway in BRAFV600E mutant melanoma cells recovered the complex formation and rescued the LKB1-AMPKalpha metabolic stress-induced response, increasing apoptosis in cooperation with the pro-apoptotic proteins Bad and Bim, and the down-regulation of Mcl-1.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 84 89 84 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
These data demonstrate that growth factor treatment and in particular oncogenic BRAFV600E induces the uncoupling of LKB1-AMPKalpha complexes providing at the same time a possible mechanism in cell proliferation that engages cell growth and cell division in response to mitogenic stimuli and resistance to low energy conditions in tumor cells. Importantly, this mechanism reveals a new level for therapeutical intervention particularly relevant in tumors harboring a deregulated RAS-Erk1/2 pathway.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 93 96 93 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Geller1">[1]</xref>
###xml 28 33 <span type="species:ncbi:9606">human</span>
Melanoma is the most lethal human skin cancer and its incidence is rapidly rising world-wide [1]. The development of effective therapeutics designed to target melanoma requires a comprehensive understanding of the underlying biochemical and genetic processes contributing to melanocytic neoplasic transformation and the subsequent progression to an advanced melanoma disease stage. Therefore, dissecting the aberrant signaling pathways that are critical to melanomagenesis and understanding the mechanisms by which these pathways interact with each other has become the recent focus of research directed at melanoma therapeutic intervention.
###end p 9
###begin p 10
###xml 357 360 357 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Chin1">[2]</xref>
###xml 467 472 467 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 558 562 558 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q61L</sup>
###xml 584 587 584 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Omholt1">[3]</xref>
###xml 876 879 876 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Tsao1">[4]</xref>
###xml 881 884 881 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Chudnovsky1">[5]</xref>
###xml 1139 1142 1139 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Chin1">[2]</xref>
###xml 447 452 <span type="species:ncbi:9606">human</span>
Dysfunctional receptor tyrosine kinase (RTK) signaling, in particular through the hepatocyte growth factor (HGF) tyrosine kinase receptor c-Met signaling pathway, is one important hallmark of melanoma. HGF signaling activates Ras-Erk1/2 and PI3K-AKT pathways, and Ras pathway activation has been shown to play a role in melanoma development and maintenance [2]. Notably, BRAF, a downstream activator in the RAS pathway is mutated in nearly 70% of human melanoma (BRAFV600E activating mutation) while NRAS activating mutations occurs in 30% of melanomas (NRASQ61L activating mutation) [3]. In addition, support for PI3K-AKT pathway signaling dysfunction in melanomagenesis has been demonstrated by the documented loss of the tumor suppressor PTEN-containing chromosomal region in 5-20% of melanomas as well as the over expression of AKT3 in the advanced stages of this disease [4], [5]. Strikingly, however, single mutations within these two pathways are not sufficient to promote melanoma development suggesting that a complex interplay of these aberrant signalling pathways, under poorly understood circumstances, promote melanomagenesis [2].
###end p 10
###begin p 11
###xml 472 475 472 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Recio1">[6]</xref>
###xml 477 480 477 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Noonan1">[7]</xref>
###xml 147 152 <span type="species:ncbi:10090">mouse</span>
###xml 378 383 <span type="species:ncbi:9606">human</span>
We chose to investigate the potential interplay among the HGF RTK signaling, the RAS Ras-Erk1/2 and the PI3K-AKT pathways using the HGF transgenic mouse model in which HGF is over-expressed and which develops melanoma in response to neonatal ultraviolet (UV) radiation. This model is unique in that it develops melanocytic neoplasms in stages that are highly reminiscent of the human cutaneous malignant melanoma with respect to biological, genetic and etiologic criteria [6], [7].
###end p 11
###begin p 12
###xml 189 192 189 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Marignani1">[8]</xref>
###xml 250 253 250 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Scott1">[9]</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Zeng1">[10]</xref>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Spicer1">[11]</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Williams1">[12]</xref>
###xml 502 506 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Dorfman1">[13]</xref>
###xml 508 512 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Boudeau1">[14]</xref>
###xml 678 682 678 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Shaw1">[15]</xref>
###xml 684 688 684 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Shaw2">[16]</xref>
###xml 690 694 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Lizcano1">[17]</xref>
###xml 891 894 891 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Marignani1">[8]</xref>
###xml 931 937 931 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 974 980 974 980 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1099 1103 1096 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota1">[18]</xref>
###xml 1105 1109 1102 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota2">[19]</xref>
###xml 1111 1115 1108 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota3">[20]</xref>
###xml 1117 1121 1114 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Xie1">[21]</xref>
###xml 1123 1127 1120 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Song1">[22]</xref>
###xml 1175 1181 1172 1178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 1219 1222 1216 1219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 1357 1360 1354 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Marignani1">[8]</xref>
###xml 1362 1366 1359 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Boudeau2">[23]</xref>
###xml 1415 1421 1412 1418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1493 1497 1490 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Xie1">[21]</xref>
###xml 1499 1503 1496 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Barnes1">[24]</xref>
###xml 1505 1509 1502 1506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Shelly1">[25]</xref>
###xml 1687 1691 1684 1688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Fogarty1">[26]</xref>
###xml 477 482 <span type="species:ncbi:10090">mouse</span>
###xml 921 926 <span type="species:ncbi:9606">human</span>
###xml 954 959 <span type="species:ncbi:10090">mouse</span>
To begin the analysis, we first searched for possible molecular candidates with potential to mediate the HGF complex signaling and identified the multitasking serine/threonine kinase, LKB1 [8] as one candidate. LKB1 is involved in cell cycle control [9], [10], cellular energy metabolism [11] and cell polarity [12]. The cellular localization and activity of LKB1 is controlled through its interaction with the STE20-related adaptor (STRAD) and the armadillo repeat-containing mouse protein 25 (Mo25); [13], [14]. These finding led to the discovery that LKB1 is the upstream kinase to AMP-activated protein kinase (AMPK) and is linked to mTOR through the AMPK-TSC1/TSC2 cascade [15], [16], [17]. LKB1 is phosphorylated on at least 8 residues, and evidence suggests that LKB1 auto-phosphorylates itself on at least four of these, whereas the other four are phosphorylated by upstream kinases [8]. Recent studies show that human LKB1Ser428 (the equivalent mouse residue is LKBSer431) is phosphorylated in response to mitogenic signals including EGF, TPA, elevated levels of cAMP as well as by PKCzeta [18], [19], [20], [21], [22], where the EGF-mediated phosphorylation of LKB1Ser428 is dependent on the activation of p90RSK. Although experiments conducted in G361 melanoma cells indicate that this residue is involved in LKB1-mediated cell growth inhibition [8], [23], and several other investigations implicate LKB1Ser431 residue in the activation of AMPK and BRK1/BRSK2 kinases (SAD-B/SAD-A) [21], [24], [25], a recent publication stating that LKB1 phosphorylation in the C-terminal is not required for regulation of AMPK BRSK1/2 and cell cycle arrest contradicts the previous findings [26].
###end p 12
###begin p 13
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lkb1</italic>
###xml 286 290 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Contreras1">[27]</xref>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Ji1">[28]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Fenton1">[29]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Shen1">[30]</xref>
###xml 310 314 310 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Avizienyte1">[31]</xref>
###xml 455 459 455 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lkb1</italic>
###xml 478 481 478 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Marignani1">[8]</xref>
###xml 502 506 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lkb1</italic>
###xml 549 553 549 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Rowan1">[32]</xref>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
Importantly, sporadic mutations in the lkb1 gene have been documented in cancers of the breast, pancreas, lung, prostate, cervical and ovary as well as in Peutz-Jeghers syndrome, a rare disorder characterized by the appearance of intestinal polyps and mucocutaneous melanocytic macules [27], [28], [29], [30], [31]. In Peutz-Jegher patients, LKB1 may function as a tumor suppressor and is associated with loss of heterozygosity or somatic mutation at the lkb1 locus (for review [8]). More importantly, lkb1 mutations have been described in melanoma [32] and based on this information we determined if LKB1 could function as a potential link between an activated RAS pathway and dysfunctional c-Met signaling and play a role in melanoma development and progression.
###end p 13
###begin p 14
###xml 41 47 41 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 205 208 205 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rsk</sup>
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota1">[18]</xref>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota2">[19]</xref>
###xml 318 324 318 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 389 394 389 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 626 631 626 631 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 869 874 869 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
###xml 459 464 <span type="species:ncbi:10090">mouse</span>
In this study, we identify the mouse LKB1Ser431 residue as a phosphorylation target, not only for EGF, but also for HGF signaling and demonstrate that this LKB1 phosphorylation is executed in an Erk1/2-p90Rsk-dependent manner, as previously described in response to EGF stimulation [18], [19]. We demonstrate that LKB1Ser428 residue is constitutively phosphorylated in cells harboring BRAFV600E activating mutations, and is found frequently phosphorylated in mouse tumor samples with an increased receptor tyrosine kinase activity suggesting a functional connection between BRAF oncogenic pathway and LKB1. Interestingly, BRAFV600E mutant cells show a very limited response to metabolic stress that appears to be mediated by mechanism that involves the uncoupling of the energy stress sensor pathway LKB1-AMPK-mTOR. Importantly, inhibition of RAS-Erk1/2 pathway in BRAFV600E mutant melanoma cell lines restores the LKB1-AMPK-mTOR pathway response to metabolic stress promoting apoptosis in coordination with the BH3-family proteins Bad and Bim and the Bcl-2 family member Mcl-1.
###end p 14
###begin title 15
Results
###end title 15
###begin title 16
###xml 16 22 16 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 58 61 58 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
HGF induces LKB1Ser428 phosphorylation in a RAS-Erk1/2-p90RSK pathway-dependent manner
###end title 16
###begin p 17
###xml 771 776 771 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 836 845 836 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g001">Figure 1A</xref>
###xml 908 914 908 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1088 1094 1088 1094 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 1172 1175 1172 1175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 1184 1188 1184 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota1">[18]</xref>
###xml 1190 1194 1190 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota3">[20]</xref>
###xml 1248 1252 1248 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Recio2">[33]</xref>
###xml 1254 1258 1254 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Leshem1">[34]</xref>
###xml 1260 1264 1260 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Trusolino1">[35]</xref>
###xml 1380 1386 1380 1386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1404 1413 1404 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g001">Figure 1B</xref>
###xml 1495 1501 1495 1501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1652 1658 1652 1658 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1712 1715 1712 1715 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 1809 1815 1809 1815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1833 1840 1833 1840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g001">Fig. 1C</xref>
###xml 1933 1939 1933 1939 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1964 1971 1964 1971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g001">Fig. 1C</xref>
###xml 2087 2090 2087 2090 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 2099 2105 2099 2105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 2107 2114 2107 2114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g001">Fig. 1C</xref>
###xml 2135 2138 2135 2138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 2168 2171 2168 2171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 2291 2297 2291 2297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 2299 2306 2299 2306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g001">Fig. 1D</xref>
###xml 2401 2407 2401 2407 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser133</sup>
###xml 2446 2449 2446 2449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 2522 2526 2522 2526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota3">[20]</xref>
###xml 168 173 <span type="species:ncbi:10090">mouse</span>
###xml 251 256 <span type="species:ncbi:10090">mouse</span>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
###xml 1106 1111 <span type="species:ncbi:10090">mouse</span>
###xml 1428 1433 <span type="species:ncbi:10090">mouse</span>
###xml 1438 1443 <span type="species:ncbi:9606">human</span>
We proposed to identify novel molecules involved in melanoma development and progression analyzing the HGF specific signaling in the UV induced HGF transgenic melanoma mouse model. To understand the HGF specific signaling contributions we used 37-31E-mouse melanoma cell line isolated from neoplasic lesions raised in the HGF transgenic-UV irradiated mice and performed a proteomic screening of the phospho-protein complexes induced after the growth factor treatment (data not shown). As a result, we identified LKB1 as a kinase that becomes phosphorylated in response to HGF. Since previous studies implicates RAS pathway in the modification of this residue we decided to use different cell lines harboring either, BRAF wild type (37-31E, 37-31T, B16F1 and MeWo) or BRAFV600E mutant cell lines (UACC903, A375 and SKMel28). As shown in Figure 1A, in isolated phospho-protein complexes from 37-31E cells, LKB1Ser431 was specifically phosphorylated in response to HGF treatment since this phosphorylation was totally prevented by the pretreatment with the specific c-Met inhibitor PHA. LKB1Ser428 (Ser431 in mouse) is phosphorylated in response to EGF through RAS-Erk1/2-p90RSK pathway [18], [20]. Since HGF triggering activates RAS and PI3K pathway [33], [34], [35], we used specific Mek1/2 (U0126) and PI3K (LY294002) inhibitors to determine which pathway was involved in the LKB1Ser431 phosphorylation. Figure 1B shows that in mouse and human melanoma cells, HGF-induced phosphorylation of LKB1Ser431 was totally abolished by the specific Mek1/2 inhibitor U0126, whereas the PI3K inhibitor LY294002 had no effect on HGF-induced phosphorylation of LKB1Ser431. Furthermore, time course experiments showed that p90RSK became phosphorylated in response to HGF and its phosphorylation profile correlated with LKB1Ser431 phosphorylation (Fig. 1C). Additionally, analysis of B16F1 melanoma cells showed that the phosphorylation of the LKB1Ser431 was p-Erk1/2 dependent (Fig. 1C) and, inhibition of Mek1/2 after HGF treatment in 37-31E cells totally abolished the phosphorylation of Erk1/2, p90RSK and LKB1Ser431 (Fig. 1C). To confirm the p90RSK participation we used the p90RSK specific inhibitor BI-D1870. Treatment of 37-31E cells with BI-D1870 abolished the HGF-mediated phosphorylation of LKB1Ser431 (Fig. 1D). The observed activation upon BI-D1870 treatment of Erk1/2 and the increased levels of p-CREBSer133 is in agreement with the suggested p90RSK negative-feedback loop that regulates Erk1/2 described by other authors [20].
###end p 17
###begin title 18
###xml 16 22 16 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 51 54 51 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
HGF induces LKB1Ser431 phosphorylation in a RAS-p90RSK dependent manner.
###end title 18
###begin p 19
###xml 168 174 160 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 184 197 176 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr202/Tyr204</sup>
###xml 631 637 615 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 646 649 630 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 649 662 633 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr359/Ser363</sup>
###xml 798 804 782 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 858 861 842 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 927 940 911 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr202/Tyr204</sup>
###xml 949 955 933 939 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 1492 1498 1460 1466 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1508 1521 1476 1489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr202/Tyr204</sup>
###xml 1532 1538 1500 1506 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser133</sup>
(A) Five microg of phospho-protein isolated complexes from samples: untreated (Control), HGF triggered (40 ng/ml) w/o PHA (0,2 microM) were resolved by SDS-PAGE. p-LKB1Ser428, p-Erk1/2Thr202/Tyr204 and Erk2 antibodies were probed against the membrane. Ponceau S staining of membrane is showed for phospho-protein extracts loading control. (B) 37-31E, 37-31T, SKMel28, and MeWo cells were treated in serum starvation conditions with HGF (40 ng/ml), U0126 (10 microM) and LY294002 (10 microM) as indicated in the figure. Western-blots show the levels of the indicated proteins. (C) Time course showing the phosphorylation of the LKB1Ser431 and p-90RSKThr359/Ser363 after HGF triggering (40 ng/ml) under serum starvation conditions. LKB1 total protein is shown as a loading control. On the right, LKB1Ser431 is phosphorylated in response to HGF in an Erk1/2-p90RSK dependent manner. Time course shows the phosphorylation of Erk1/2Thr202/Tyr204 and LKB1Ser428 in B16F1 cells. Down below, 37-31E melanoma cells were serum starved and triggered with HGF (40 ng/ml) for 5 minutes. Then, cells were treated with the Mek1/2 specific inhibitor U0126 (10 microM) for the indicated increasing times. Fifty microg of total lysates were resolved by SDS-PAGE and membrane was probed with the indicated antibodies. (D) 37-31E cells were treated for 10 min in serum starvation with HGF (40 ng/ml) in the presence or absence of U0126 (10 microM) or BI-D1870 (10 microM). Western-blots show the levels of p-LKB1Ser431, p-Erk1/2Thr202/Tyr204 and p-CREBSer133.
###end p 19
###begin p 20
###xml 29 35 29 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 99 102 99 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
These results show that, LKB1Ser428 is phosphorylated in response to HGF treatment in an Erk1/2-p90RSKdependent manner.
###end p 20
###begin title 21
###xml 4 10 4 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 130 135 130 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
LKB1Ser428 is phosphorylated in response to different growth factors and is highly phosphorylated in melanoma cells harboring BRAFV600E mutations and in tumor samples
###end title 21
###begin p 22
###xml 248 254 248 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 312 316 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota1">[18]</xref>
###xml 597 603 593 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 653 660 649 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g002">Fig. 2A</xref>
###xml 718 721 714 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 764 770 760 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 772 779 768 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g002">Fig. 2A</xref>
###xml 150 155 <span type="species:ncbi:9606">human</span>
###xml 160 165 <span type="species:ncbi:10090">mouse</span>
Next, we investigated if this post-translational modification was broader in scope. We tested several growth factors related to cancer development in human and mouse melanoma cell lines to check whether or not these ligands were able to induce LKB1Ser428 phosphorylation. As suggested by previous investigations [18], all ligands tested, including HGF, EGF, basic fibroblast growth factor (FGF2), insulin like growth factor 1 (IGF-1), platelet derived growth factor (PDGF), tumor necrosis factor-alpha (TNF-alpha), herregulin, insulin and phorbol-ester tumor promoter TPA were able to induced LKB1Ser428 phosphorylation in a cell type dependent manner (Fig. 2A). In all cases, the ligands that activated Erk1/2 and p90RSK kinases led to the phosphorylation of LKB1Ser428 (Fig. 2A).
###end p 22
###begin title 23
###xml 4 10 4 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 92 97 92 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 124 129 <span type="species:ncbi:10090">mouse</span>
LKB1Ser431 (Ser428 human) is phosphorylated in response to different growth factors, in BRAFV600E mutant melanoma cells and mouse tumor samples.
###end title 23
###begin p 24
###xml 397 402 389 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 418 423 410 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 442 447 434 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 647 653 635 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 663 676 651 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr202/Tyr204</sup>
###xml 685 702 673 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK Thr359/Ser363</sup>
###xml 793 799 781 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 812 825 800 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr202/Tyr204</sup>
###xml 449 454 <span type="species:ncbi:9606">human</span>
###xml 836 841 <span type="species:ncbi:10090">mouse</span>
###xml 921 936 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1011 1015 <span type="species:ncbi:10090">mice</span>
(A) B16F1, 37-31T and MeWo cells were serum starved and treated with HGF (40 ng/ml), EGF (100 ng/ml), FGF2 (100 ng/ml), Herregulin (50 ng/ml), IGF-1 (50 ng/ml), PDGF (50 ng/ml), TNF-alpha (100 ng/ml) Insulin (100 nM) and TPA (200 nM). Fifty microg of total lysates were separated by SDS-PAGE and same membranes were incubated against the indicated antibodies. (B) MeWo (BRAF wild type), A375 (BRAFV600E), SKMel28 (BRAFV600E) and UACC903 (BRAFV600E) human melanoma cells were growth in complete medium (CM) or serum starvation (SF) conditions as indicated. Fifty microg of total lysates were analyzed by SDS-PAGE. The phosphorylation status of LKB1Ser428, p-Erk1/2Thr202/Tyr204 and p-90RSK Thr359/Ser363 is shown. Total Erk1/2 is used as a loading control. Cell genotypes are showed. (C) p-LKB1Ser431 and p-Erk1/2Thr202/Tyr204 levels in mouse melanoma tumor samples. Samples 1-7 primary tumors raised in HGF-UV irradiated transgenic mice. Samples 8 and 9 show xenograph tumors generated from 37-31E cells in FVB mice with high and low p-Erk1/2 levels, respectively. As a control fifty micrograms of protein from 37-31E melanoma cell line treated with HGF (40 ng/ml) for 10 minutes was added (Total lysates, T.L.). Same membrane was blotted against the indicated antibodies. Quantifications of phospho-proteins normalized against total protein are showed in the graphs below.
###end p 24
###begin p 25
###xml 166 169 166 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Omholt1">[3]</xref>
###xml 219 225 219 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 279 284 279 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 436 441 436 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 500 506 500 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 601 608 601 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g002">Fig. 2B</xref>
###xml 117 122 <span type="species:ncbi:9606">human</span>
###xml 239 244 <span type="species:ncbi:9606">human</span>
###xml 392 397 <span type="species:ncbi:9606">human</span>
###xml 532 537 <span type="species:ncbi:9606">human</span>
The aberrant regulation of the Ras-Erk1/2 pathway represents one of the hallmarks in cancer. Considering that 70% of human melanomas harbor BRAF activating mutations [3], we determined the phosphorylation status of LKB1Ser428 in different human melanoma cell lines harboring BRAFV600E activating mutations in serum free and complete medium conditions. As expected, SKMel28, A375, and UACC903 human melanoma cell lines harboring the BRAFV600E mutation demonstrated a constitutively phosphorylated LKB1Ser428 residue whereas the MeWo human melanoma cell line that harbors the wild type alleles did not (Fig. 2B).
###end p 25
###begin p 26
###xml 180 186 180 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 253 259 253 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 435 442 435 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g002">Fig. 2C</xref>
###xml 317 332 <span type="species:ncbi:10090">transgenic mice</span>
Based on the above results, tumor samples with a deregulated tyrosine kinase pathway and/or with enhanced RAS-mediated mitogenic activity would be expected to exhibit elevated LKB1Ser428 phosphorylation. In this matter, the phosphorylation state of LKB1Ser431 in spontaneous tumor samples raised in UV-irradiated HGF transgenic mice and in xenographed tumors from the 37-31E-melanoma cells correlated with elevated levels of p-Erk1/2 (Fig. 2C).
###end p 26
###begin p 27
All together, these data indicated the existence of a RAS pathway and LKB1 crosstalk suggesting that LKB1 might be involved in some of the RAS-Erk1/2 induced-responses, and more importantly would be contributing to BRAF oncogenic signaling.
###end p 27
###begin title 28
BRAF mutant melanoma cells have a dysfunctional LKB1-AMPK energy stress-induced pathway response
###end title 28
###begin p 29
###xml 240 246 236 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 359 365 355 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 557 562 553 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 646 651 642 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1050 1057 1042 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g003">Fig. 3A</xref>
###xml 1197 1204 1189 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g003">Fig. 3A</xref>
###xml 1426 1433 1410 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g003">Fig. 3A</xref>
###xml 1575 1582 1559 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g003">Fig. 3A</xref>
###xml 1742 1746 1722 1726 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S428</sup>
###xml 1748 1755 1728 1735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g003">Fig. 3A</xref>
###xml 1890 1894 1862 1866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Dokladda1">[36]</xref>
###xml 1896 1903 1868 1875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g003">Fig. 3B</xref>
###xml 2305 2309 2277 2281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Davies1">[37]</xref>
###xml 2311 2315 2283 2287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sanders1">[38]</xref>
###xml 2317 2321 2289 2293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Suter1">[39]</xref>
###xml 2467 2474 2435 2442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g003">Fig. 3C</xref>
###xml 2515 2520 2483 2488 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 2626 2631 2594 2599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 2856 2863 2824 2831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g003">Fig. 3D</xref>
###xml 2909 2914 2877 2882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 3015 3021 2979 2985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g003">Fig 3D</xref>
Melanoma cells are especially resistant to different types of stress. LKB1 is the AMPKalpha upstream kinase that becomes phosphorylated in response to metabolic stress controlling protein synthesis through mTOR pathway. Considering the LKB1Ser428 phosphorylation as a read out of the RAS and LKB1 pathways interaction, the constitutive phosphorylation of LKB1Ser428 in BRAF mutant cells suggested a possible interplay between LKB1-AMPK pathway and BRAF oncogenic signaling. Therefore, we investigated the LKB1-AMPK pathway activation in three different BRAFV600E mutant melanoma cell lines under low energy conditions and the contribution of BRAFV600E signaling to the energy sensor pathway. To test this hypothesis we starved BRAF mutant melanoma cells under serum free and low glucose conditions in the presence or absence of the Mek1/2 inhibitor U0126, and investigated the activation of LKB1-AMPK-mTOR pathway. UACC903, SKMel28 and A375 cells showed a very limited response to energy withdrawal as measured by the induction of phospho-AMPKalpha (Fig. 3A). Under these conditions all cells retained considerable mTOR activity as indicated by the phosphorylation levels of ribosomal protein S6 (Fig. 3A). However, the addition of U0126 (10 microM) recovered AMPKalpha pathway activation in response to low energy conditions resulting in the complete abrogation of mTOR activity as indicated by phospho-S6 ribosomal protein (Fig. 3A). In contrast, 37-31E melanoma cells harboring wild type BRAF did not show this effect by the addition of U0126 under low energy conditions (Fig. 3A). Interestingly, the re-activation of the AMPKalpha pathway in BRAF mutant cells correlated with the total inactivation of Erk1/2 and the unphosphorylated LKB1S428 (Fig. 3A). Importantly, the addition of U0126 up to 10 microM in serum free high glucose conditions did not induce the activation of AMPKalpha [36] (Fig. 3B). To confirm the reconnection of the AMPK pathway after inhibition of oncogenic BRAF signaling we used AICAR (5-Aminoimidazole-4-carboxyamide ribonucleoside) instead of low glucose in order to stimulate the activation of the AMPK pathway. As expected, the addition of AICAR, which increases AMPK phosphorylation levels by a mechanism that appears to be due to the inhibition of AMPK dephosphorylation [37], [38], [39], slightly increased the p-AMPK levels in serum starvation. The addition of U0126 inhibitor resulted in a clear increment the p-AMPKalpha levels (Fig. 3C). Since this effect was observed in BRAFV600E mutant cells, we repeated the experiments using the BRAF inhibitor sorafenib. Notably, inhibition of BRAFV600E signaling with sorafenib recovered the activation of AMPK pathway in response to metabolic stress. Interestingly, sorafenib treatment under low glucose condition reduced Erk2 protein levels by a currently unknown mechanism (Fig. 3D). Importantly, experiments knocking-down BRAFV600E performed in serum free and low glucose medium also resulted in an increased of p-AMPKalpha levels (Fig 3D).
###end p 29
###begin title 30
###xml 28 33 28 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Inhibition of oncogenic BRAFV600E signaling restores the limited response to metabolic stress of BRAF mutant melanoma cell lines.
###end title 30
###begin p 31
###xml 1090 1096 1066 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 1104 1110 1080 1086 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr172</sup>
###xml 1120 1133 1096 1109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr202/Tyr204</sup>
###xml 1140 1145 1116 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser79</sup>
###xml 1522 1526 1490 1494 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T172</sup>
###xml 1534 1540 1502 1508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1549 1562 1517 1530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr202/Tyr204</sup>
###xml 1572 1578 1540 1546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser133</sup>
###xml 1880 1884 1844 1848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T172</sup>
###xml 1894 1907 1858 1871 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr202/Tyr204</sup>
###xml 1934 1937 1898 1901 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rsk</sup>
(A) BRAF mutant melanoma cells have a limited response to energy withdrawal that is restored by U0126 treatment. Fifty micrograms of total lysates from UACC903, A375, SKMel28 and 37-31E melanoma cells grown in serum free high glucose medium (H.G.), serum free low glucose medium (L.G.) or serum free low glucose medium (L.G.) plus 10 microM of U0126 for 4 hours were separated by SDS-PAGE. Western-Blot shows the activation status of proteins in the RAS and LKB1-AMPK-mTOR pathways. (B) U0126 inhibitor treatment does not activate AMPK. UACC903 A375 and SKMel28 melanoma cells were grown in high glucose medium with serum in the absence or presence of 1 microM, 5 microM or 10 microM of U0126. Total protein lysates were subjected to SDS-PAGE. Western-blot shows the phosphorylation state of AMPKalpha in the presence of different concentrations of U0126. (C) Inhibition of BRAF signaling increases cell response to AICAR. UACC903 and SKMel28 cells were grown in complete medium; cells were treated with AICAR (1 mM) for 4 h in the presence or absence of U0126 (10 microM) inhibitor. p-LKB1Ser428, p-AMPKThr172, p-Erk1/2Thr202/Tyr204, p-ACCSer79 levels were checked by western blot. (D) Sorafenib treatment and siRNA BRAF knockdown restores the metabolic stress pathway in BRAF mutant melanoma cells. In the left panel, UACC903, A375 and SKMel28 melanoma cells were grown in low glucose serum free medium+/-EGF (50 ng/ml) for 4 h in the presence or absence of U0126 (10 microM) Western blots show the levels of p-AMPKalphaT172, p-LKB1Ser431 p-Erk1/2Thr202/Tyr204 and pCREBSer133 proteins under the different conditions. In the right panel SKMel28 cells were transfected with either a scramble siRNA or BRAF siRNA. 72 hours after transfection, cells were starved either in high glucose (H.G.) or low glucose (L.G.) medium for six hours. Western-blots show the levels of p-AMPKalphaT172, p-Erk1/2Thr202/Tyr204 and BRAF proteins. (E) p90Rsk inhibitor BI-D1870 (10 microM), does not restore the metabolic stress pathway. UACC903, A375 and SKMel28 melanoma cells were grown in low glucose serum free medium+/-EGF (50 ng/ml) for 4 h in the presence or absence of BI-D1870 (10 microM). Western blots show the levels of the indicated proteins under the different conditions.
###end p 31
###begin p 32
###xml 34 37 34 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 246 249 246 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 364 371 364 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g003">Fig. 3E</xref>
###xml 422 428 422 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 569 575 569 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser133</sup>
###xml 621 624 621 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 670 674 670 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota3">[20]</xref>
In addition, we tested whether p90RSK signaling was mediating the observed effect using the p90RSK specific inhibitor BI-D1870. Experiments were done in the presence of EGF to assured the activation of RAS pathway. Treatment of cells with the p90RSK inhibitor BI-D1830 did not recover the cells response to low energy conditions as indicated by the p-AMPK levels (Fig. 3E) suggesting, that the oncogenic BRAF-mediated LKB1Ser428 phosphorylation was not sufficient to account for the observed response. As previously shown, BI-D1870 treatment induced the Erk1/2 and CREBSer133 phosphorylation mediated by the suggested p90RSK negative-feedback loop that regulates Erk1/2 [20].
###end p 32
###begin p 33
###xml 362 368 362 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
Altogether these data show evidences that indicate that melanoma cells harboring oncogenic BRAF have a diminished response to metabolic stress. Importantly, the inhibition of the oncogenic BRAF signaling, that connects RAS pathway to LKB1, restored the AMPK-mediated energy stress sensor pathway. However the results also indicate that the inhibition of the LKB1Ser428 phosphorylation is not enough to recover the pathway LKB1-AMPK-mTOR response, suggesting the existence of additional mechanisms.
###end p 33
###begin title 34
###xml 42 47 42 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Growth factor treatment and oncogenic BRAFV600E induce LKB1-AMPK disassembly
###end title 34
###begin p 35
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Boudeau1">[14]</xref>
###xml 334 338 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Shaw1">[15]</xref>
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Shaw2">[16]</xref>
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Lizcano1">[17]</xref>
###xml 1243 1250 1227 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g004">Fig. 4A</xref>
###xml 1363 1365 1347 1349 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KD</sup>
###xml 1530 1536 1510 1516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 1665 1667 1645 1647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1683 1688 1663 1668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S431A</sup>
###xml 1701 1706 1681 1686 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S431D</sup>
###xml 1742 1744 1722 1724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KD</sup>
###xml 1851 1853 1827 1829 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1862 1864 1838 1840 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KD</sup>
###xml 2022 2027 1990 1995 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S431A</sup>
###xml 2035 2040 2003 2008 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S431D</sup>
###xml 2196 2203 2160 2167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g004">Fig. 4B</xref>
###xml 1615 1620 <span type="species:ncbi:10090">mouse</span>
The LKB1 tumor suppressor kinase activity is not related to its phosphorylation state [14]. Thus, its contribution to the different biological processes is likely to be mediated by its interaction with other proteins and/or its cellular localization. LKB1 controls protein synthesis and cell growth through the AMPK-TSC1/TSC2 cascade [15], [16], [17]. Mitogenic responses coordinate simultaneously cell growth with cell division. Since the activation of AMPK-TSC1/TSC2 pathway by LKB1 controls energy metabolism and protein synthesis, we examined whether the growth factor treatment leads to LKB1-AMPK dissociation, providing a mechanism that would assure cell growth upon a mitogenic stimulus and resistance to energy stress conditions. To investigate the underlying mechanism, we transfected 293T cells with Flag-tagged LKB1 and GST-AMPKalpha and then treated the cells with or without EGF in order to activate RAS pathway. After immunoprecipitation of the Flag-LKB1 complexes we checked for the presence of GST-AMPKalpha in the immunocomplexes. The data indicated that some fraction of AMPKalpha is constitutively bound to LKB1. Interestingly, treatment of cells with the growth factor induced dissociation of the LKB1-AMPKalpha complexes (Fig. 4A). Moreover, this effect was totally independent of LKB1 kinase activity since Flag-tagged kinase dead LKB1 (LKB1KD) reproduced exactly the same result. Since growth factor stimulation promoted LKB1-AMPKalpha disassembly and this effect correlated with the phosphorylation of LKB1Ser428 upon growth factor stimulation, we examined the role of the Ser428 (Ser431 in mouse) residue on this effect. We transfected LKB1WT wild type, LKB1S431A mutant, LKB1S431D phospho-mimetic mutant and the LKB1KD constructs together with GST-AMPKalpha in 293T cells and repeated the previous experiment. Again when LKB1WT and LKB1KD were transfected the EGF treatment promoted the disassembly of the LKB1-AMPKalpha complex. However, GST-AMPKalpha did not form a complex with either the LKB1S431A or LKB1S431D mutants, suggesting that, in response to growth factors, the Ser428 residue would be involved in the binding or stability of the LKB1-AMPKalpha complexes (Fig. 4B).
###end p 35
###begin title 36
###xml 32 37 32 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Growth factor treatment and BRAFV600E promotes LKB1-AMPKalpha disassembly.
###end title 36
###begin p 37
###xml 780 786 772 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1261 1265 1237 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T172</sup>
###xml 1517 1521 1485 1489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T172</sup>
###xml 1816 1821 1776 1781 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
(A) 293T cells were transiently transfected for 48 h with Flag-LKB1, Flag-LKB1KD (kinase dead) and GST-AMPKalpha as indicated. Then, cells were treated with 100 ng/ml of EGF for 10 min. Immunocomplexes pulled down with an anti-Flag-resin were separated by SDS-PAGE and proteins present in the complexes were analyzed by western blot. Total lysates show the transfection controls and the response to growth factor treatment. (B) 293T cells were transiently transfected with the constructs indicated. Then, cells were serum starved for 2 h and treated with 100 ng/ml of EGF for 10 min and protein complexes were immunoprecipitated with anti-Flag-resin. Protein complexes were separated by SDS-PAGE. Levels of GST-AMPKalpha, Flag-LKB1 constructs and the phosphorylation state of LKB1Ser431 in the complexes are shown. Quantification of the amount of GST-AMPKalpha normalized to the Flag-LKB1 immunoprecipitated is represented in the graph. Total lysates are shown for control transfection of the different samples. (C) Endogenous LKB1 from UACC903 and A375 melanoma cells growing in low glucose medium (L.G.) with or without 10 microM U0126 was immunoprecipitated. Western-blot from the immunoprecipitated samples was probed against LKB1, AMPKalpha and p-AMPKalphaT172 antibodies. On the right, total lysates from SKMel28 melanoma cells growing in complete medium (High Glucose, H.G.) low glucose medium (L.G.) in the presence or absence of 10 microM U0126 were subjected to immunoprecipitation with the anti-p-AMPKalphaT172. Samples were separated by SDS-PAGE. Total lysates (T.L.) from low glucose plus U0126 treated cells are showed as a control. Western-Blot of the immunoprecipitated samples was performed against total AMPKalpha antibody. (D) Hela cells were transfected with Flag-LKB1, GST-AMPKalpha and myc-BRAFV600E or and empty vector as indicated. Flag-LKB1 was immunoprecipitated and western-blots from immunoprecipitated samples were probed against the indicated antibodies. Graph shows the quantification of the AMPK bound to LKB1.
###end p 37
###begin p 38
###xml 628 635 616 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g004">Fig. 4C</xref>
###xml 704 708 688 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T172</sup>
###xml 790 794 770 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T172</sup>
###xml 905 912 885 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g004">Fig. 4C</xref>
###xml 1116 1121 1092 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1184 1189 1160 1165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1284 1291 1260 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g004">Fig. 4D</xref>
The above data suggested that the limited response to metabolic stress of BRAF mutant melanoma cells could be caused by the dissociation of LKB1-AMPKalpha complexes. Thus, the inhibition of BRAF signaling by U0126 inhibitor would permit the reconnection of the pathway. To confirm that, we performed an immunoprecipitation of the endogenous LKB1 in the BRAF mutant melanoma cells and examined the AMPKalpha association under low energy conditions with or without U0126 inhibitor. UACC903 and A375 melanoma cells showed an increase in the number of AMPKalpha molecules associated to LKB1 when BRAF signaling pathway was blocked (Fig. 4C). This re-assembly was also associated with an increase in AMPKalphaT172 phosphorylation levels. Similar results were obtained when endogenous p-AMPKalphaT172 was immunoprecipitated from SKMel28 melanoma cells under same conditions, confirming the suggested mechanism (Fig. 4C). Additionally, we reconstitute the system in Hela cells that do not express endogenous LKB1. Hela cells were transfected with Flag-LKB1 and GST-AMPKalpha in the presence or absence of oncogenic myc-BRAFV600E under low glucose conditions. The expression of oncogenic BRAFV600E induced the complex dissociation that was totally rescued by the addition of U0126 inhibitor (Fig. 4D).
###end p 38
###begin p 39
###xml 214 219 214 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 422 428 414 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
These data showed evidences that support the growth factor treatment and RAS pathway activation mediated disassembly of the LKB1-AMPK complexes. Importantly the inhibition of the RAS pathway in cells harboring BRAFV600E mutation restores the LKB1-AMPKalpha pathway by permitting the re-association of the LKB1-AMPKalpha complexes. Furthermore, these data also suggested that although growth factor stimulation induces LKB1Ser428 phosphorylation, additional mechanisms should be involved promoting the RAS pathway-dependent LKB1-AMPK disassembly.
###end p 39
###begin title 40
###xml 49 54 45 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Restoration of the LKB1-AMPKalpha pathway in BRAFV600E melanoma cells under energy stress conditions induces apoptosis in coordination with Bad, Bim and Mcl-1
###end title 40
###begin p 41
###xml 53 58 53 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 332 336 328 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Shaw2">[16]</xref>
###xml 406 411 402 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 534 538 530 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sheridan1">[40]</xref>
###xml 540 544 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Wang1">[41]</xref>
###xml 1547 1553 1539 1545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g005">Fig 5A</xref>
###xml 1635 1642 1627 1634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g005">Fig. 5A</xref>
###xml 1849 1855 1841 1847 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 2077 2081 2057 2061 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T172</sup>
###xml 2083 2090 2063 2070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g005">Fig. 5B</xref>
###xml 2404 2411 2384 2391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g005">Fig. 5B</xref>
###xml 778 783 <span type="species:ncbi:120290">Guava</span>
Next, investigated the cell survival response of BRAFV600E mutant melanoma cell lines with a restored LKB1-AMPKalpha pathway under stress energy conditions. According to the accepted mechanism, elevation of intracellular AMP levels will activate LKB1 that in turn activates AMPK and regulates apoptosis in response to energy stress [16]. Additionally, it has been shown that blocking BRAF signaling in BRAFV600E mutant cell lines for long periods of time (24-48 hours) promotes apoptosis through the regulation of BH3-family proteins [40], [41]. We subjected UACC903 and A375 melanoma cells to metabolic stress conditions for a maximum of 12 hours in the presence or absence of the Mek1/2 inhibitor. Then, we measured cell viability and apoptosis by nuclear staining exclusion (Guava ViaCount) and Annexin V and propidium iodide (PI) double staining. UACC903 and A375 melanoma cell lines showed some spontaneous apoptosis under normal growing conditions: 5.71% and 3.27% respectively. The addition of Mek1/2 inhibitor for 12 hours in high glucose medium did not promote any increment in the apoptosis rate (UACC903 5.38% and A375 2.70%). Glucose starvation for 12 hours resulted in slight increase in the number of double positive Annexin V-PI cells respect normal growing conditions: 1.27 fold for UACC903 cells and 2.35 fold for A375 cells. However, the restoration of the LKB1-AMPKalpha pathway by inhibition of Mek1/2 under low glucose conditions resulted in a considerable number of apoptotic cells (5.7 and 6.4 fold increase respectively); (Fig 5A). Similar results were observed when viable cells were analyzed by PI exclusion (Fig. 5A). The results were correlated with the molecular status of the pathways implicated in a time course fashion. As shown before, the inhibition of Erk1/2 phosphorylation resulted in the decrease of phopho-LKB1Ser428 levels and the restoration of the LKB1-AMPKalpha pathway. In turn, the LKB1-AMPKalpha pathway was able to sense the low energy conditions as soon as 4 hours after glucose starvation, indicated by the levels of p-AMPKalphaT172 (Fig. 5B). Interestingly, the increase in the number of apoptotic cells did not correlate with p53 stabilization. On the contrary, p53 levels were down-regulated under these conditions in all cell lines, suggesting the participation of BRAF signaling in the stabilization of p53 and a p53-independent apoptotic mechanism (Fig. 5B).
###end p 41
###begin title 42
###xml 49 54 45 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
Restoration of the LKB1-AMPKalpha pathway in BRAFV600E melanoma cells induces apoptosis under energy stress conditions.
###end title 42
###begin p 43
###xml 1456 1460 1428 1432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T172</sup>
###xml 1484 1497 1452 1465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thr202/Tyr204</sup>
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 488 493 <span type="species:ncbi:120290">Guava</span>
###xml 634 639 <span type="species:ncbi:9606">human</span>
###xml 1395 1400 <span type="species:ncbi:120290">Guava</span>
(A) UACC903, A375 and SKMel28 human melanoma cells were grown in complete medium (H.G.), or low glucose medium (L.G.) with or without 10 microM of the Mek1/2 specific inhibitor U0126 for 12 h. Then, Annexin V and PI (propidium iodide) positive cells were analyzed by flow cytometry. Histograms show the result from FACS analysis. Graphs on the right show the percentage of viable and dead cells in a parallel experiment under the same conditions determined by nuclear staining exclusion (Guava-ViaCount). (B) Time course at 4 and 12 hours showing the LKB1-AMPKalpha pathway status under the same conditions. UACC903, A375 and SKMel28 human melanoma cells were grown in complete medium (high glucose H.G.), low glucose medium (L.G.) with or without 10 microM of the Mek1/2 specific inhibitor U0126 for the times indicated. Fifty micrograms of total protein lysates were separated by SDS-PAGE and same membranes were blotted against the indicated antibodies. All experiments were done at least three times. Representative experiments are shown. (C) UACC903 cells were transfected either with a scramble siRNA or with equimolar amounts of AMPKalpha1 and AMPKalpha2 siRNAs for a total concentration of 100 nM. 72 hours after transfection cells were starved in low glucose medium for 6 hours in the presence or absence of 10 microM of U0126. Dead cells were quantified by nuclear staining exclusion (Guava-ViaCount). Western-blots show the levels of p-AMPKalphaT172, AMPKalpha and p-Erk1/2Thr202/Tyr204 under the different conditions. (D) UACC903 and A375 melanoma cells were grown in complete medium (H.G. cm), serum free high glucose medium (H.G. sf), serum free low glucose medium (L.G.), serum free complete medium plus U0126 10 microM (H.G.+U0126) and low glucose serum free medium plus U0126 10 microM (L.G.+U0126) for 12 hours. The levels of Bim, phospho-Bad and Mcl-1 are showed under the different experimental conditions.
###end p 43
###begin p 44
###xml 323 332 319 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g005">figure 5C</xref>
###xml 442 446 434 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T172</sup>
In order to establish a causal link among the inhibition of BRAF signaling, the AMPK pathway re-activation, and the increased number of dead cells, we knocked-down AMPKalpha in UACC903 melanoma cells and investigated the response under low glucose conditions to the inhibition of the oncogenic BRAF signaling. As showed in figure 5C, blocking BRAF signal under low energy conditions in control cells resulted in elevated levels of p-AMPKalphaT172 together with an increment in the number of dead cells. However, AMPKalpha knock-down cells did not show any increase in the number of dead cells under similar conditions.
###end p 44
###begin p 45
###xml 96 101 96 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 115 119 115 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sheridan1">[40]</xref>
###xml 327 329 327 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EL</sub>
###xml 601 603 597 599 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EL</sub>
###xml 654 661 650 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g005">Fig. 5D</xref>
As mentioned previously, BRAF suppresses apoptosis, targeting the BH3-family of proteins in BRAFV600E mutant cells [40]. In high glucose medium the addition of the U0126 inhibitor for 12 hours caused a small decrease of p-Bad and the Bcl-2 family member Mcl-1 protein levels together with a slight increase in the amount of BimEL. Interestingly, when the LKB1-AMPKalpha pathway was restored under low glucose conditions, the increased number of dead cells correlated with a stronger biochemical response including the complete de-phosphorylation of Bad, the stabilization of the non-phosphorylated BimEL isoform and the drastic down-regulation of Mcl-1 (Fig. 5D).
###end p 45
###begin p 46
###xml 308 310 308 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EL</sub>
Our results indicated that in a BRAF mutant context, the reactivation of LKB1-AMPK-mTOR pathway under low energy conditions together with the inhibition of oncogenic BRAF signaling for short periods of time, promoted a pronounced apoptosis response through the de-phosphorylation of Bad, stabilization of BimEL and the down-regulation of Mcl-1.
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 286 289 286 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Recio1">[6]</xref>
###xml 291 294 291 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Noonan1">[7]</xref>
###xml 626 630 626 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota1">[18]</xref>
###xml 716 722 716 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 749 752 749 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 872 877 872 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1123 1128 1123 1128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1371 1376 1371 1376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 178 183 <span type="species:ncbi:10090">mouse</span>
###xml 271 276 <span type="species:ncbi:9606">human</span>
###xml 420 425 <span type="species:ncbi:10090">mouse</span>
###xml 508 513 <span type="species:ncbi:10090">mouse</span>
###xml 837 842 <span type="species:ncbi:9606">human</span>
The understanding of the molecular and biochemical mechanisms contributing to melanoma development and progression is critical for therapeutical intervention. The UV-induced HGF mouse melanoma model recapitulates chronologically and histopathologically all the stages of human melanoma [6], [7]. We investigated the potential interplay among the HGF RTK signaling, the RAS-Erk1/2 and the PI3K-AKT pathways using the HGF mouse model. In neoplasic melanoma cells isolated from spontaneous tumors raised in the mouse model, we identified LKB1 as one of the molecules responsive to HGF triggering. As previously described for EGF [18], we show that HGF and several other growth factors induce the phosphorylation of LKB1Ser431 through the Ras-Erk1/2-p90RSK pathway. Interestingly, this residue appears to be constitutively phosphorylated in human melanoma cells harboring BRAFV600E activating mutation as an indicator of the connection between RAS pathway and LKB1. The role of LKB1 in response to growth factors, and its connection to the RAS pathway, is mostly unknown. Our results show that melanoma cells harboring the BRAFV600E oncogenic mutation have a very limited response to metabolic stress. Interestingly, the inhibition of the BRAF signaling restores the ability of the cells to sense the low energy conditions. Notably, growth factor treatment and oncogenic BRAFV600E leads to the uncoupling of LKB1-AMPKalpha complexes, suggesting a mechanism that disconnects the energy sensor pathway, which is involved in controlling cell growth through the mTOR pathway in response to low energy conditions. Furthermore, inhibition of BRAF oncogenic signaling promotes the association of the LKB1-AMPKalpha complexes and results in an increase of apoptosis in response to metabolic stress.
###end p 48
###begin p 49
###xml 321 327 321 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 336 339 336 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 378 382 378 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota1">[18]</xref>
###xml 384 388 384 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota2">[19]</xref>
###xml 418 424 418 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 521 524 521 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 592 596 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota1">[18]</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sapkota2">[19]</xref>
###xml 1055 1060 1055 1060 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1206 1212 1206 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 1300 1305 1300 1305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1407 1413 1407 1413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser431</sup>
###xml 1260 1265 <span type="species:ncbi:9606">human</span>
###xml 1425 1430 <span type="species:ncbi:9606">human</span>
###xml 1462 1467 <span type="species:ncbi:10090">mouse</span>
Our screening for the discovery of novel molecules involved in HGF signaling in melanoma cells allowed us to identify by DIGE analysis proteins that were directly modified in response to c-Met activation by HGF (data not shown). Previously, it has been described that EGF and forskolin promote the phosphorylation of LKB1Ser428 in a p90RSK and PKA dependent manner respectively [18], [19]. Our results showed that LKB1Ser431 phosphorylation occurs in response to HGF and other different growth factors in a RAS-Erk1/2-p90RSK dependent manner as initially suggested by previous investigations [18], [19]. Interestingly, and according to siRNA knock down experiments (data not shown), cells expressing less than five percent of the LKB1 pool still respond to this stimulus, suggesting that LKB1 would have a relevant role in the mitogenic response to growth factors. Virtually all cancers have aberrant signaling of receptor tyrosine kinases (RTKs), growth factors autocrine loops or activating mutations in the RAS pathway (RAS activating mutations or BRAFV600E mutation). We therefore hypothesized that LKB1 would be mediating some of the effects of the RAS and BRAF oncogenes. In agreement with this, LKB1Ser428 appears to be constitutively phosphorylated in human melanoma cell lines harboring BRAFV600E activating mutations as an indicator of the interplay between RAS pathway and LKB1. Furthermore, LKB1Ser431 (Ser428 in human) tends to be phosphorylated in mouse tumor samples harboring deregulated tyrosine kinase activities or increased mitogenic signaling, suggesting the direct participation of LKB1 in tumor biology.
###end p 49
###begin p 50
###xml 100 104 100 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Dorfman1">[13]</xref>
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Boudeau1">[14]</xref>
###xml 260 263 260 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Marignani1">[8]</xref>
###xml 420 424 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Spicer1">[11]</xref>
###xml 426 430 426 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Shaw2">[16]</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Williams1">[12]</xref>
###xml 465 469 465 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Spicer1">[11]</xref>
###xml 501 505 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Zeng1">[10]</xref>
###xml 659 665 659 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 892 895 888 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Marignani1">[8]</xref>
###xml 897 901 893 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Xie1">[21]</xref>
###xml 903 907 899 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Boudeau2">[23]</xref>
###xml 909 913 905 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Shelly1">[25]</xref>
###xml 915 919 911 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Fogarty1">[26]</xref>
LKB1 activity is controlled through its interaction with the STE20-related adaptor (STRAD) and Mo25 [13], [14]. LKB1 can be phosphorylated at eight or more different residues, where the modifications at these amino acids have no effect on LKB1 kinase activity [8]. In the last five years a number of publications have reported several critical roles for LKB1 in different biological processes such as: energy metabolism [11], [16], cell polarity and division [12], [11] and transcriptional regulation [10]. However, most of these studies rely on the presence or absence of LKB1 in these processes. Our data show that growth factor treatment induces both, LKB1Ser428 phosphorylation and the dissociation of LKB1-AMPKalpha complexes. The participation of this residue in growth inhibition, cell polarity and the activation of the LKB1 downstream kinases (AMPK, BRSK1/2) have been controversial [8], [21], [23], [25], [26]. Indeed, our results regarding the participation of this residue in the growth factor-mediated dissociation of the LKB1-AMPKalpha complexes are not conclusive and more research is needed in order to elucidate the complete role of this residue. Moreover, we can no exclude the participation of additional residues or proteins in the process.
###end p 50
###begin p 51
###xml 98 102 94 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Shaw1">[15]</xref>
###xml 104 108 100 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Shaw2">[16]</xref>
###xml 110 114 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Lizcano1">[17]</xref>
###xml 860 865 848 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1184 1190 1168 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g006">Fig. 6</xref>
###xml 1315 1319 1291 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Dokladda1">[36]</xref>
###xml 1847 1853 1807 1813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g005">Fig 5A</xref>
###xml 1958 1964 1918 1924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser428</sup>
###xml 1984 1987 1944 1947 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 2252 2258 2208 2214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g006">Fig. 6</xref>
LKB1 is the upstream kinase of AMPKalpha and is linked to mTOR through the AMPK-TSC1/TSC2 cascade [15], [16], [17] controlling cell growth under energy stress conditions. One possible interpretation of our results would be that the dissociation of the LKB1-AMPKalpha complex would provide a mechanism to avoid interruption of protein synthesis through this pathway while cells are responding to a mitogenic stimulus. In this matter, the activation of RAS-Erk1/2 pathway would engage biochemical mechanisms to coordinate cell growth and division to assure cell proliferation. Importantly, the deregulation of the AMPK-mTOR axis by the dissociation of the LKB1-AMPKalpha complex in cells harboring RAS pathway activating mutations could represent an advantage for proliferation and a significant resistance increased to metabolic stress conditions. Notably, BRAFV600E mutant melanoma cell lines showed a limited sensitivity in response to low energy conditions. Treatment of cells with the Mek1/2 inhibitor U0126 allowed the formation of endogenous LKB1-AMPKalpha complexes and restored the energy sensor pathway in response to low energy conditions, supporting the proposed mechanism (Fig. 6). Mek1/2 inhibitors (U0126, PD98059) have been reported to activate AMPK at 20 microM concentration, but not at 5-10 microM [36]. These experiments were done in glucose free medium and in the presence of growth factors with high levels of phospho-Erk1/2. According to our data the inhibition of the Erk1/2 pathway under low energy conditions would allow the re-association of LKB1-AMPKalpha, which in turn would result in an increase the levels of p-AMPKalpha. Furthermore, our data showed that in high glucose medium the addition of U0126 (10 microM) or sorafenib (data not shown) had no effect on AMPKalpha phosphorylation in all BRAF mutant cell lines (Fig 5A). Up-to-date the connection between RAS pathway and LKB1 has been limited to the phosphorylation of LKB1Ser428 residue through p90RSK. However, our results indicate that this modification is not enough to mediate the observed effect, suggesting the existence of additional biochemical mechanisms mediated by Erk1/2 that will account for the LKB1-AMPKalpha dissociation mediated by the RAS pathway (Fig. 6).
###end p 51
###begin title 52
A model of the metabolic stress response regulation by oncogenic BRAF in melanoma cells.
###end title 52
###begin p 53
###xml 104 109 104 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 300 303 300 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rsk</sup>
Resistance to stress conditions is essential for melanoma cells survival. We propose that oncogenic BRAFV600E signaling (left panel) protects to apoptosis by regulating BH3-family members and confers resistance to low energy conditions promoting the uncoupling of LKB1 and AMPK through Erk1/2 and p90Rsk. Under this condition BRAF mutant cells have a limited response to low energy conditions. On the right panel the inhibition of BRAF signaling allows the formation of the LKB1-AMPK complexes restoring the energy stress pathway and promoting the down-regulation of anti-apoptotic proteins such as Mcl1. The activation of AMPK by metabolic stress conditions and the inhibition of BRAF signaling would have synergistic effects promoting apoptosis.
###end p 53
###begin p 54
###xml 208 211 204 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Marignani1">[8]</xref>
###xml 378 383 374 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g006">Fig 6</xref>
###xml 966 970 958 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Huang1">[42]</xref>
###xml 1312 1316 1304 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Melnikova1">[43]</xref>
###xml 1318 1322 1310 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Persons1">[44]</xref>
###xml 1455 1459 1447 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Jones1">[45]</xref>
###xml 792 796 <span type="species:ncbi:10090">mice</span>
The activation of AMPKalpha by LKB1 under energy stress, stimulates glucose uptake and fatty acid oxidation to increase ATP production, inhibits protein synthesis and protects cells from undergoing apoptosis [8]. Surprisingly, the inhibition of Erk1/2 pathway in BRAF mutant melanoma cell lines subjected to metabolic stress resulted in an increase in the number of dead cells (Fig 6). Interestingly, our experiments knocking-down AMPKalpha suggests a causal link among the inhibition of oncogenic BRAF signaling, the reconstitution of the energy sensor pathway and the resulting cell death. In agreement with the interplay between the oncogenic signaling and AMPK is the recent finding where the activation of AMPK pathway by administration of metformin, phenformin or A-769662 to PTEN(+/-) mice significantly delayed tumor onset, demonstrating that LKB1 is required for activators of AMPK to inhibit mTORC1 signaling as well as cell growth in PTEN-deficient cells [42]. Interestingly, the increased apoptosis rate did not correlate with the stabilization of p53, indicating that the mechanism was apparently p53-independent and that BRAF oncogenic signaling was participating in the stabilization of p53. In fact, it is known that under genotoxic-stress conditions, Erk1/2 signaling mediates p53 stabilization [43], [44]. Furthermore, the AMPK-induced p53 activation has been reported to promote cell survival in response to glucose deprivation in MEFs [45], while our data in BRAF mutated melanoma cells clearly showed an increase in apoptosis.
###end p 54
###begin p 55
###xml 122 126 122 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Sheridan1">[40]</xref>
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Wang1">[41]</xref>
###xml 283 285 283 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EL</sub>
###xml 387 391 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Marani1">[46]</xref>
###xml 586 591 586 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g006">Fig 6</xref>
###xml 681 685 681 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Chetoui1">[47]</xref>
Recent publications have shown that oncogenic BRAF can suppress apoptosis through targeting BH3-only proteins Bad and Bim [40], [41]. Our results indicate that the inhibition of oncogenic BRAF signaling at 12 h promotes a slight de-phosphorylation of Bad and the stabilization of BimEL, most likely, by inhibiting its Erk1/2-dependent phosphorylation and proteasome-mediated degradation [46]. The reactivation of the LKB1-AMPK-mTOR pathway under low energy conditions by the inhibition of BRAF signaling led to a more pronounced effect that included a drastic down-regulation of Mcl-1 (Fig 6). Interestingly, Mcl-1 has been shown to be an important melanoma anti-apoptotic protein [47].
###end p 55
###begin p 56
###xml 105 110 105 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 438 443 434 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 788 793 776 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004771-g006">Fig 6</xref>
In conclusion, in this report we show that activation of RAS pathway by growth factors and oncogenic BRAFV600E results in the dissociation of LKB1-AMPKalpha. These results, permit us to speculate that under normal growth conditions, this biochemical mechanism, through the activation of RAS pathway, could be involved in the coordination of two important processes in cell proliferation: cell growth and cell division. Interestingly, BRAFV600E mutant melanoma cells have minimal response to energy stressed conditions due to the constitutive dissociation of the LKB1-AMPKalpha complexes. However, under metabolic stress conditions the inactivation of BRAF oncogenic signaling restores the LKB1-AMPKalpha-mTOR pathway-promoting apoptosis in collaboration with BH3-only proteins and Mcl-1 (Fig 6). Importantly, this mechanism reveals a new level for therapeutical intervention triggering apoptosis of tumor cells. This might be particularly relevant in tumors harboring a deregulated RAF-Erk1/2 pathway that survive in energy stress conditions.
###end p 56
###begin title 57
Materials and Methods
###end title 57
###begin title 58
Cell lines
###end title 58
###begin p 59
###xml 55 59 55 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004771-Recio2">[33]</xref>
###xml 617 618 607 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 366 371 <span type="species:ncbi:9606">human</span>
###xml 531 538 <span type="species:ncbi:8060">Pollock</span>
37-31E and 37-31T cells have been described previously [33]. The 293T, Hela, SKMel28, MeWo, A375 and B16F1 cell lines were from ATCC. The 293T cells and Hela cells were maintained in DMEM (Gibco) with 10% FBS and penicillin/streptomycin, while the 37-31E and 37-31T cells were supplemented with EGF (5 ng/ml) (Invitrogen) and Insulin (4 microg/ml) (Invitrogen). The human melanoma cell lines SKMel28 and were grown in MEM (ATCC) supplemented with 10% FBS plus penicillin/streptomycin (Gibco). UACC903 were a gift from J. Trent (P. Pollock), Tgen Phoenix, Arizona. All cell lines were growth under 37degreesC and 5% CO2 conditions. For low glucose conditions cells were put in DMEM (Gibco) or MEM (Gibco) low glucose medium plus penicillin/streptomycin for at least 4 h.
###end p 59
###begin title 60
Phospho-protein isolation
###end title 60
###begin p 61
37-31E cells were serum starved for two hours and then triggered with 40 ng/ml of HGF (R&D) for 10 minutes in the presence or absence of 0.2 microM of the c-Met specific inhibitor PHA (Sugen-Pfizer). Cells were then lysed according to the phospho-protein purification kit (Qiagen Inc.), and phospho-proteins purified according to manufacturer instructions.
###end p 61
###begin title 62
Plasmids
###end title 62
###begin p 63
###xml 15 17 15 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 44 46 44 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KD</sup>
###xml 75 80 75 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S431A</sup>
###xml 107 112 107 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S431D</sup>
###xml 320 325 316 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 359 364 355 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
pCMV5-Flag-LKB1WT wild type, pCMV5-Flag-LKB1KD kinase dead, pCMV5-Flag-LKB1S431A mutant and pCMV5-Flag-LKB1S431D mutant were obtained from Dario Alessi (University of Dundee). pEBG-2t-GST-AMPKalpha was a kind gift from Jose Miguel Lizcano and Jose Manuel Lopez Blanco (Autonomous University of Barcelona). pLPCX-myc-BRAFV600E, was subcloned from pEB- myc-BRAFV600E (obtained from Richard Marais, ICRF).
###end p 63
###begin title 64
Cell transfection
###end title 64
###begin p 65
293T cells were seeded at 60% confluence the day before transfection. Cells were transiently transfected with Lipofectamine reagent (Invitrogen Inc.) following the manufacturer's protocol. Cells were treated and lysed 36-48 h after transfection.
###end p 65
###begin title 66
siRNA transfection experiments
###end title 66
###begin p 67
###xml 16 21 <span type="species:ncbi:9606">human</span>
###xml 58 63 <span type="species:ncbi:9606">human</span>
Scramble siRNA, human BRAF siRNA On target-smartpool, and human siRNA AMPKalpha1 and AMPKalpha2 On-target-smartpools were purchased from Dharmacon. 100 nM siRNA was transfected into cells using Lipofectamine 2000 (Invitrogen Inc.) following manufacturer protocol. Experiments were performed 72 hours after transfection.
###end p 67
###begin title 68
Reagents and Western Blot analysis
###end title 68
###begin p 69
###xml 795 798 779 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RSK</sup>
###xml 1333 1344 <span type="species:ncbi:3704">horseradish</span>
PHA c-Met specific inhibitor (Pfizer) was diluted in DMSO and used at the concentrations indicated. Mek1/2 inhibitor U0126 and PI3K inhibitor LY294002 (Cell Signaling) were used at 10 microM concentration. P90RSK inhibitor BI-D1870 was purchased from MSI/WTB University of Dundee and used at 10 microM. Cells were treated with the inhibitors for 2 hours under serum starvation and then treated with HGF (40 ng/ml) for 10 min. Five microg of phospho-proteins or 50 microg of total protein lysates were separated by SDS-PAGE and transferred to a PVDF membrane (Millipore). The membranes were blocked in 5% milk (Santa Cruz) and blotted against different primary antibodies. ERK2 and LKB1 were from Santa Cruz. Anti-DYKDDDDK (Flag), phospho-Erk1/2 (Thr202/Tyr204), Erk1/2, phospho-ACC (Ser79), p-90RSK (Thr359/Ser363), AMPKalpha, p-AMPK (Thr172), phospho-S6 ribosomal protein (Ser235/236); phosho-Bad (Ser112), anti-Bad and Bim were purchased from Cell Signaling. Additionally p-Bad (Ser112) was purchased from Genscript Co., Anti-GST polyclonal antibody and anti-Flag was purchased from Sigma-Aldrich and Genscript Co. and GAPDH was purchased from Trevigen. Mcl-1 antibody was from DAKO. Anti-Flag resin was obtained from Sigma-Aldrich and glutathione-resin was purchased from Amersham and Genscript Co. Membranes were developed using horseradish linked secondary antibodies (GE Healthcare) and ECL (GE Healthcare).
###end p 69
###begin title 70
Immunoprecipitations
###end title 70
###begin p 71
36-48 h after transfection cells were treated as needed and lysed in RIPA Buffer containing a protease cocktail II inhibitor (Sigma-Aldrich). 800-1000 microg of total protein was subjected to immunoprecipitation with 30 microl Flag-resin or 30 microl of Glutathion-resin. Then, samples were washed three times with RIPA buffer and SDS-loading sample buffer was added to the samples. Samples were separated by SDS-PAGE.
###end p 71
###begin title 72
Cell viability and apoptosis assays
###end title 72
###begin p 73
###xml 52 57 <span type="species:ncbi:120290">Guava</span>
Cell viability and dead cells were counted by using Guava ViaCount reagent (Gevara Technologies) cell counter (ViaCount). Apoptosis was measured using the Annexin V-EGFP apoptosis detection kit (Genscript corporation) following the manufacturer's protocol. Positive cells for Annexin V-EGFP and propidium iodide staining were analyzed and quantified by flow cytometry (FACScalibur).
###end p 73
###begin title 74
Image analysis
###end title 74
###begin p 75
Bands from tumor samples were quantified using NIH1.6 Image software. Normalization of p-proteins was performed against the normalized amount of the total phosphorylated protein. Other proteins were normalized against GAPDH.
###end p 75
###begin p 76
We want to thank, Joan Seoane, Juan Carlos Rodriguez-Manzaneque, Hector G. Palmer and Stephan Tenbaum for useful discussions. We also are grateful to Cristina Ferrer for technical assistance with the proteomic work.
###end p 76
###begin title 77
References
###end title 77
###begin article-title 78
Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions.
###end article-title 78
###begin article-title 79
Malignant melanoma: genetics and therapeutics in the genomic era.
###end article-title 79
###begin article-title 80
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
###end article-title 80
###begin article-title 81
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
###end article-title 81
###begin article-title 82
###xml 7 12 <span type="species:ncbi:9606">human</span>
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
###end article-title 82
###begin article-title 83
Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis.
###end article-title 83
###begin article-title 84
###xml 33 37 <span type="species:ncbi:10090">mice</span>
Neonatal sunburn and melanoma in mice.
###end article-title 84
###begin article-title 85
LKB1, the multitasking tumour suppressor kinase.
###end article-title 85
###begin article-title 86
LKB1 catalytically deficient mutants enhance cyclin D1 expression.
###end article-title 86
###begin article-title 87
LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation.
###end article-title 87
###begin article-title 88
LKB1 kinase: master and commander of metabolism and polarity.
###end article-title 88
###begin article-title 89
LKB1 and AMPK in cell polarity and division.
###end article-title 89
###begin article-title 90
STRAD{alpha} Regulates LKB1 Localization by Blocking Access To Importin-{alpha}, and by Association With Crm1 and Exportin-7.
###end article-title 90
###begin article-title 91
Analysis of the LKB1-STRAD-MO25 complex.
###end article-title 91
###begin article-title 92
The LKB1 tumor suppressor negatively regulates mTOR signaling.
###end article-title 92
###begin article-title 93
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.
###end article-title 93
###begin article-title 94
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1.
###end article-title 94
###begin article-title 95
Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell vrowth.
###end article-title 95
###begin article-title 96
Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome.
###end article-title 96
###begin article-title 97
BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.
###end article-title 97
###begin article-title 98
Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells.
###end article-title 98
###begin article-title 99
Protein kinase C zeta -dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells.
###end article-title 99
###begin article-title 100
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Functional analysis of LKB1/STK11 mutants and two aberrant isoforms found in Peutz-Jeghers Syndrome patients.
###end article-title 100
###begin article-title 101
LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons.
###end article-title 101
###begin article-title 102
LKB1/STRAD promotes axon initiation during neuronal polarization.
###end article-title 102
###begin article-title 103
C-terminal phosphorylation of LKB1 is not required for regulation of AMPK, BRSK1, BRSK2, or cell cycle arrest.
###end article-title 103
###begin article-title 104
Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.
###end article-title 104
###begin article-title 105
LKB1 modulates lung cancer differentiation and metastasis.
###end article-title 105
###begin article-title 106
###xml 27 32 <span type="species:ncbi:9606">human</span>
LKB1 protein expression in human breast cancer.
###end article-title 106
###begin article-title 107
###xml 63 68 <span type="species:ncbi:9606">human</span>
The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma.
###end article-title 107
###begin article-title 108
LKB1 somatic mutations in sporadic tumors.
###end article-title 108
###begin article-title 109
Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas.
###end article-title 109
###begin article-title 110
Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1.
###end article-title 110
###begin article-title 111
Preferential binding of Grb2 or phosphatidylinositol 3-kinase to the met receptor has opposite effects on HGF-induced myoblast proliferation.
###end article-title 111
###begin article-title 112
A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth.
###end article-title 112
###begin article-title 113
PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway.
###end article-title 113
###begin article-title 114
###xml 146 151 <span type="species:ncbi:9606">human</span>
###xml 192 198 <span type="species:ncbi:9913">bovine</span>
5'-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC.
###end article-title 114
###begin article-title 115
Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family.
###end article-title 115
###begin article-title 116
Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase.
###end article-title 116
###begin article-title 117
Oncogenic B-RAFV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim.
###end article-title 117
###begin article-title 118
###xml 23 28 <span type="species:ncbi:9606">human</span>
Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
###end article-title 118
###begin article-title 119
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.
###end article-title 119
###begin article-title 120
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase.
###end article-title 120
###begin article-title 121
Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin.
###end article-title 121
###begin article-title 122
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.
###end article-title 122
###begin article-title 123
Role of Bim in the survival pathway induced by Raf in epithelial cells.
###end article-title 123
###begin article-title 124
Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
###end article-title 124
###begin p 125
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 125
###begin p 126
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by: Instituto Carlos III, Fondo de Investigaciones Sanitarias projects PI050227, PI080653, Marie Curie Reintegration Grant MIRG-CT-2005-029135 and Fundacion Mutua Madrilena (FMM). The Proteomics Laboratory at IR-HUVH is a member of the National Spanish Institute for Proteomics (PROTEORED), supported by Fundacion Genoma Espana. REP fellowship was sponsored by Fundacio Institut de Recerca Vall d'Hebron. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 126

